Clinical Trials Directory

Trials / Conditions / Small Bowel Cancer

Small Bowel Cancer

14 registered clinical trials studyying Small Bowel Cancer — 4 currently recruiting.

StatusTrialSponsorPhase
WithdrawnA Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With
NCT06690281
National Cancer Institute (NCI)Phase 2
RecruitingLocally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
NCT06101277
University of California, DavisN/A
RecruitingIndividualized Dose Escalation of 5-FU for Gastrointestinal Cancer
NCT05780684
Dartmouth-Hitchcock Medical CenterN/A
Active Not RecruitingStudy of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
NCT05565417
Immunitas TherapeuticsPhase 1 / Phase 2
RecruitingIntraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointesti
NCT05277766
University Hospital, GhentPhase 1
RecruitingStereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
NCT04498767
European Organisation for Research and Treatment of Cancer - EORTCN/A
CompletedThe Registry of Oncology Outcomes Associated With Testing and Treatment
NCT04028479
Taproot Health—
CompletedClinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chem
NCT04526886
Dartmouth-Hitchcock Medical CenterN/A
CompletedA Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies
NCT04316078
Sheba Medical CenterN/A
Active Not RecruitingRCT of Mobile Apps & FitBit v. Usual Care
NCT03623464
Weill Medical College of Cornell UniversityN/A
UnknownSurgery With Extended (D3) Mesenterectomy for Small Bowel Tumors
NCT05670574
Sykehuset i Vestfold HFN/A
TerminatedEffects of S-1 and Capecitabine on Coronary Artery Blood Flow
NCT02216149
Heikki JoensuuPhase 2
CompletedProspective Analysis of Hypersensitivity Reactions to Oxaliplatin
NCT00831571
Dana-Farber Cancer Institute—
AvailableExpanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
NCT04566393
xCures—